Keyword: John Milligan

Gilead CEO John Milligan racked up $26M in 2018 pay, on paper at least, while incoming chief Daniel O'Day is in line for a cool $30M this year.

Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.

RBC Capital Markets investors picked an oncology expert as their top candidate to replace Gilead CEO John Milligan.

Gilead Sciences' two top executives, Chairman John C. Martin and CEO John Milligan, are leaving at the end of 2018.

Gilead's promotion of Andrew Dickinson, and a fresh licensing deal, could signal that Gilead's looking outside its own walls for growth opportunities.

Gilead may have some exciting prospects ahead, but for now, its cash-cow hepatitis C business is a big drag. The good news? It's a 'trough year.'

A host of challenges that drove Gilead's revenues down 14% last year didn’t stop its board from boosting the CEO’s pay package to $15.4 million.

Kite Pharma CEO Arie Belldegrun turned a single buyout bid into a $12 billion deal by capitalizing on suitor Gilead’s need to make a game-changing deal.

Kite Pharma's ability to handle the complex manufacturing of its CAR-T cancer treatment is one reason Gilead is paying $11.9 billion for the company.

Gilead Sciences, under pressure from a flagging hep C franchise, agreed to plunk down nearly $12 billion for Kite Pharma just ahead of a blockbuster CAR-T approval.